Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China.
|Abstract||To describe the clinical features and effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A(H1N1) virus infection.|
|Author||Yu, H; Liao, Q; Yuan, Y; et al|
|Key phrase||Adolescent Adult Antiviral Agents Child China Disease Outbreaks Female Humans Influenza A Virus, H1N1 Subtype Influenza, Human Male Oseltamivir RNA, Viral Retrospective Studies Risk Factors Treatment Outcome Virus Shedding Young Adult|
Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection.
|Abstract||The safety of high-dose oseltamivir during treatment of 2009 H1N1 influenza A infection for critically ill patients is unknown. Here we report on a case patient with severe, delayed-onset neuropsychiatric symptoms after administration of high-dose oseltamivir. Clinicians should be vigilant to the possible increased risk of complications associated with high-dose oseltamivir therapy for 2009 H1N1 influenza A infection.|
|Author||Nakamura, K; Schwartz, BS; Lindegårdh, N; et al|
|Key phrase||Adult Antiviral Agents Confusion Hallucinations Humans Influenza A Virus, H1N1 Subtype Influenza, Human Leukemia, Promyelocytic, Acute Male Neurotoxicity Syndromes Oseltamivir Transplantation, Autologous|
Antiviral treatment for the control of pandemic influenza: some logistical constraints.
|Abstract||Disease control programmes for an influenza pandemic will rely initially on the deployment of antiviral drugs such as Tamiflu, until a vaccine becomes available. However, such control programmes may be severely hampered by logistical constraints such as a finite stockpile of drugs and a limit on the distribution rate. We study the effects of such constraints using a compartmental modelling approach. We find that the most aggressive possible antiv ... [truncated at 450 characters in length]|
|Author||Arinaminpathy, N; Mclean, AR;|
|Key phrase||Antiviral Agents Communicable Disease Control Disease Outbreaks Humans Influenza A Virus, H5N1 Subtype Influenza, Human Models, Biological|
HSV-2 sacral radiculitis (Elsberg syndrome).
|Author||Eberhardt, O; Küker, W; Dichgans, J; et al|
|Key phrase||Acyclovir Adult Antiviral Agents Female Ganglia, Spinal Herpes Simplex Herpesvirus 2, Human Humans Hypesthesia Leukocytosis Myelitis Radiculopathy Sacrum Syndrome Urinary Retention|
Pharmacokinetic properties of anti-influenza neuraminidase inhibitors.
|Abstract||Neuraminidase inhibitors are the mainstay of anti-influenza treatment. Oseltamivir is the most widely used drug but is currently available only as an oral formulation. Resistance spreads rapidly in seasonal H1N1 influenza A viruses, which were universally resistant in 2008, because of the H275Y mutation in the neuraminidase (NA) gene. Oseltamivir is a prodrug for the active carboxylate metabolite. Ex vivo conversion in blood samples may have conf ... [truncated at 450 characters in length]|
|Author||Chairat, K; Tarning, J; White, NJ; et al|
|Key phrase||Animals Antiviral Agents Drug Interactions Enzyme Inhibitors Humans Influenza, Human Neuraminidase|